Ozagrel

CHEMBL11662 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
228.2 g/mol
LogP
1.6
Phase
4

A thromboxane synthase inhibitor used in Japan to treat ischemic stroke and prevent thrombosis by reducing production of thromboxane A2, a potent promoter of platelet aggregation and vasoconstriction. It helps restore blood flow and prevents further clot formation in affected blood vessels.

Peso Molecular

228,2500 g/mol

LogP

1,60

TPSA

55,10 Ų

Regra dos 5 de Lipinski

Aprovado

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1

InChI

InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+

Molecular Formula

C13H12N2O2

HBD / HBA

1 / 3

Ligações Rotacionáveis

4

Átomos Pesados

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A thromboxane synthase inhibitor used in Japan to treat ischemic stroke and prevent thrombosis by reducing production of thromboxane A2, a potent promoter of platelet aggregation and vasoconstriction. It helps restore blood flow and prevents further clot formation in affected blood vessels.

Yes, Ozagrel is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL11662. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5282440. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.